Edwards Lifesciences Corporation reports developments in structural heart medical technology, including surgical tissue valves, transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies. Company news commonly covers the SAPIEN TAVR platform, PASCAL transcatheter edge-to-edge repair technology, the EVOQUE transcatheter tricuspid valve replacement system, and RESILIA tissue used in surgical and transcatheter valve innovations.
Recurring updates include quarterly results, clinical-trial data presented at cardiovascular meetings, reimbursement and guideline developments affecting valve procedures, product pipeline commentary, healthcare conference appearances, access initiatives for structural heart treatment, and finance leadership or governance announcements.
Edwards Lifesciences (EW) plans to release quarterly operating results and host an earnings conference call on November 4, 2026.
The results cover the quarter ended September 30, 2026 and are scheduled for release after the market closes. The call begins at 5:00 p.m. ET that day and will be available live and archived on the company's investor relations website.
Edwards Lifesciences (NYSE: EW) will host an investor event on Nov. 2 in conjunction with the TCT scientific symposium in San Diego. The event runs from 5:00 to 6:00 PM Pacific Time and includes live questions and answers with physicians and Edwards management. A live webcast will be available on the investor relations website, with an archive accessible later that day.
Edwards Lifesciences (NYSE: EW) received FDA approval for the AUTUS Size-Adjustable Valve for pediatric patients with congenital heart disease requiring pulmonary valve replacement.
The valve can expand as a child grows through a minimally invasive catheter procedure, potentially reducing repeat open-heart surgeries. Approval was based on the pivotal study, which met its primary safety and effectiveness endpoints: 100% of patients were free from device-related complications through 30 days, with no AUTUS valve reinterventions through six months. Among patients completing one-year follow-up, 100% had a mean pressure gradient across the right ventricular outflow tract of 40 mmHg or less, less than moderate backward blood flow through the pulmonary valve, and no valve reinterventions. Patients will be followed for 10 years. The approval expands Edwards’ congenital treatment options.
Edwards Lifesciences (EW) commented on the updated national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) issued by the Centers for Medicare & Medicaid Services. The company said the policy is an important step toward improving and expanding patient access to TAVR and reinforces the role of the multidisciplinary Heart Team.
Edwards highlighted that the modernized NCD supports a more streamlined patient care journey and gives Heart Teams greater flexibility to tailor evaluation and treatment to each patient’s clinical needs. The company stated that the updated policy creates opportunities for patients and TAVR programs and reaffirmed confidence in its previously communicated 2026 financial guidance. Edwards plans to provide 2027 and longer-term guidance at its investor conference in December.
Edwards Lifesciences (EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, September 16, 2026. Chief executive officer Bernard Zovighian is scheduled to present at 10:00 a.m. ET, with chief financial officer Doretta Mistras also taking part in the conference.
A live webcast and same-day archived replay will be available on the company’s investor relations website.
Edwards Lifesciences (NYSE: EW) reported second quarter 2026 net sales of $1.74 billion, up 13.6% year over year, with constant currency growth of 12.5%. TAVR sales rose 11.3% to about $1.3 billion, TMTT sales grew 47.3% to $195.9 million, and Surgical sales increased 6.5% to $284 million.
GAAP diluted EPS from continuing operations was $0.42, while adjusted EPS was $0.78. Gross margin was 77.5% and operating margin 29.5% (30.0% adjusted). The company raised 2026 constant currency sales growth guidance to 10–11%, increased TAVR and TMTT guidance, and reaffirmed adjusted EPS of $2.95–$3.05. Edwards ended the quarter with $2.9 billion in cash and $600 million in debt and expects full‑year operating margin at the high end of its 28–29% range.
Edwards Lifesciences (NYSE: EW) will release operating results for the quarter ended June 30, 2026 after the market closes on Thursday, July 23, 2026, and will host an earnings conference call at 5:00 p.m. ET the same day. Investors can join by phone or via a live and archived webcast on the company’s Investor Relations website at ir.edwards.com.
Edwards Lifesciences (NYSE:EW) reported new structural heart data at New York Valves 2026 across aortic, mitral and tricuspid therapies.
Highlights include baseline characteristics from the PROGRESS moderate aortic stenosis trial, seven-year PARTNER 3 SAPIEN 3 durability results, EARLY TAVR findings, and large registries for PASCAL and SAPIEN M3 mitral therapies.
Edwards Lifesciences (NYSE: EW) announced that Theodora “Doretta” Mistras will become corporate vice president and chief financial officer, effective at the end of May. Mistras succeeds Scott Ullem, who announced his planned transition in October and has served as CFO since 2014. The company highlighted Mistras’ CFO role at Viatris since March 2024, prior senior investment-banking roles, and dual bachelor’s degrees from the University of Pennsylvania and Wharton.
The company said Ullem will support a thoughtful transition and serve as a strategic advisor in the months ahead.
Edwards Lifesciences (NYSE: EW) reported 10-year COMMENCE aortic trial results showing long-term durability of its RESILIA tissue for surgical aortic valves. Key 10-year outcomes: 97.9% freedom from structural valve deterioration, 97.8% freedom from reoperation for SVD, and 98.6% freedom from non-structural valve dysfunction, with sustained hemodynamics. The FDA-approved, pivotal, prospective multicenter study was presented May 2, 2026, at the AATS meeting and supports RESILIA's role in lifetime valve management.